Thailand PGT CMS

标签： pgt-a

  • Why Similar Age and AMH Results Can Lead to Different IVF Plans

    Two people can be the same age, hold AMH reports that look almost identical, and still leave consultations with noticeably different IVF plans. That is not necessarily a sign that one clinic is better informed than the other. It usually means the plan was built from more than two numbers.

    Age and AMH are useful starting points. They help a clinician think about how many eggs might be available and how age relates to chromosome risk in embryos. Neither one, on its own, tells the whole story of how someone will respond to stimulation, what protocol suits them, or whether genetic testing of embryos belongs in their plan.

    What AMH measures, and what it does not

    AMH (anti-Müllerian hormone) is generally used as a marker of ovarian reserve — a rough indication of how many small follicles are present and how the ovaries may respond to stimulation. It is a quantity signal, not a quality signal.

    AMH does not measure:

    • the chromosomal status of individual eggs;
    • whether an egg will fertilise;
    • whether an embryo will implant;
    • whether a pregnancy will be ongoing.

    This is why a low AMH does not automatically mean pregnancy is impossible, and a high AMH does not automatically mean a straightforward cycle. A high AMH can also sit alongside a diagnosis such as polycystic ovary syndrome (PCOS), which changes how stimulation is planned and how ovarian hyperstimulation syndrome (OHSS) risk is managed.

    Age works differently. It is one of the factors clinicians weigh when discussing embryo chromosome risk and when PGT-A might be raised as an option. But age is a population-level signal, not a prediction about any one person’s embryos. For a fuller discussion of how age interacts with embryo testing, see PGT for advanced maternal age in Thailand.

    The inputs a clinician weighs beyond age and AMH

    When a plan differs between two people with similar numbers, the difference usually comes from clinical context — the history, examinations and prior treatment experience that sit around the lab results.

    Ovarian findings on ultrasound

    Antral follicle count (AFC) is measured on ultrasound and is often read alongside AMH. The two usually agree, but not always. When they diverge, the clinician has to decide which signal to trust more for that person, and that judgement can shift the starting dose.

    Hormone results and cycle day

    FSH, estradiol, thyroid function and other results, interpreted against the day of the cycle they were drawn, add context. A result read on the wrong cycle day can be misleading, which is one reason dated, complete records matter.

    Previous stimulation response

    If someone has already had a cycle, the number of eggs retrieved, the dose used, how the ovaries responded and whether OHSS occurred are often more informative than any baseline number. A previous poor or exaggerated response is a strong reason to change protocol.

    Male factor and semen parameters

    Semen analysis findings influence whether standard IVF or ICSI is discussed, and whether additional sperm selection techniques are considered. These decisions sit alongside, not inside, the AMH result.

    Uterine and pelvic factors

    Fibroids, polyps, adenomyosis, endometriosis, the appearance of the lining and any planned surgical review can change timing and whether a fresh or frozen transfer is preferred.

    Endocrine and other diagnoses

    PCOS, thyroid conditions and other endocrine issues can affect stimulation strategy, OHSS risk and when a cycle should start.

    Prior pregnancy loss or genetic findings

    A history of loss, a known inherited condition in the family, or a chromosomal rearrangement carried by a parent changes the conversation entirely. PGT-M addresses a known monogenic condition, and PGT-SR addresses chromosomal structural rearrangements; both are designed around a specific history rather than offered generically. The HFEA overview of PGT-M and PGT-SR explains that these tests answer different questions and should be discussed with a treating team and genetic counsellor. A comparison of how PGT-A and PGT-M differ is covered in PGT-A vs PGT-M in Thailand.

    Patient priorities and practical constraints

    Two people with the same clinical picture may still choose different plans because of cost, travel time, work commitments, willingness to bank embryos across several cycles, or views on embryo testing. These are legitimate inputs, not afterthoughts.

    How those inputs change concrete plan elements

    The same baseline numbers can lead to different choices at several decision points:

    Plan element What can shift it
    Starting gonadotropin dose AMH, AFC, prior response, PCOS diagnosis, age
    Protocol choice (antagonist, long agonist, mild) Prior response, OHSS risk, endometriosis, scheduling
    Adjuvant add-ons Individual history and the clinician’s reading of the evidence
    Trigger strategy and OHSS management Follicle number, estradiol level, PCOS, prior OHSS
    Fresh versus freeze-all transfer Lining, hormone levels, OHSS risk, PGT-A plans
    Number of cycles before transfer Embryo yield so far, banking goals, age, cost and travel
    Whether PGT-A is discussed Age, prior loss, prior aneuploidy, patient priorities

    None of these rows can be decided from age and AMH alone. That is the practical reason two similar-looking reports can produce different plans.

    A short worked contrast

    Consider two hypothetical patients, both 36 and both with an AMH in a similar mid-range band. This is an illustration of how context changes decisions, not a description of real cases or expected outcomes.

    Patient A has an AFC that matches her AMH, regular cycles, no prior IVF, a normal semen analysis and no pelvic findings. Her clinician might discuss a standard antagonist protocol at a moderate starting dose, a fresh transfer if her lining and hormone levels allow, and PGT-A as an option to weigh rather than a default.

    Patient B has a lower AFC than her AMH would suggest, a previous cycle with a modest egg yield on a standard dose, and a partner with a semen analysis that raises the question of ICSI. Her clinician might discuss a higher starting dose or a different protocol, a freeze-all approach to preserve options, and a conversation about whether to bank embryos across more than one cycle before transfer.

    Same age. Similar AMH. Different plans — because the plan was built from the context, not the headline numbers.

    Where PGT-A fits, and where it does not

    PGT-A assesses chromosome number in cells sampled from an embryo. The HFEA patient information on PGT-A notes that testing has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. Biopsy itself carries a risk: the HFEA PGT-A FAQ states that embryo biopsy can cause damage and prevent further development.

    Results also need careful reading. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample; technical factors can contribute, and a sampled result does not establish the cell composition of the whole embryo. The ASRM committee opinion on mosaic PGT-A results recommends discussing such results and their uncertainty with the treating clinician and a genetic counsellor.

    So PGT-A is a discussion, not a checkbox. Whether it is raised, and how much weight it carries, depends on age, history, embryo numbers and what matters to the patient. How results are reported is covered in how to read PGT-A results.

    Records that make a remote review more useful

    If you are comparing plans or seeking a remote opinion, the quality of the review depends on the quality of the records. A useful set usually includes:

    • dated AMH, FSH, estradiol and thyroid results, with the cycle day noted;
    • ultrasound reports showing antral follicle count and any pelvic findings;
    • semen analysis reports with dates;
    • prior stimulation records: protocol, doses, follicle counts, trigger, eggs retrieved, fertilisation and embryo outcomes;
    • any OHSS history or cycle cancellation reasons;
    • prior pregnancy, loss or genetic testing reports;
    • a short written summary of your own priorities: timing, travel, budget range and views on embryo testing.

    Organising these before a consultation makes the conversation more specific. Guidance on preparing records is in how to organise medical records for a remote fertility review.

    Questions worth putting to your clinician

    These are neutral prompts for a licensed clinician, who is the right person to interpret your results and recommend a plan:

    • Which findings in my history are shaping your recommended protocol, and why?
    • How do my AMH and antral follicle count compare, and which are you weighting more?
    • What would change your starting dose or protocol if my response differs from expectation?
    • What is my OHSS risk, and how would you manage it?
    • Would you recommend a fresh or frozen transfer for me, and what would change that?
    • Is PGT-A relevant to my situation, and what are the limitations in my case?
    • If I need more than one cycle, how would we plan that around my travel and budget?

    Thailand PGT can help organise records, prepare questions and coordinate appointments or remote consultations. The coordination service does not interpret results, diagnose or recommend protocols — those conversations belong with your treating clinician. Scope and any fees are confirmed individually.

  • Why Egg Number Is Only One Part of an IVF Discussion About Low Ovarian Reserve

    If an ovarian reserve test has come back low, the first number you hear can feel like the whole story. It is not. Ovarian reserve describes an estimate of how many eggs remain in the ovaries. It does not measure the quality of any single egg, and it does not tell you what will happen in one particular IVF cycle. Egg number is one input among several, and the weight it deserves depends on your age, your history, your partner’s or donor’s sperm findings, and what you are actually trying to achieve.

    What ovarian reserve tests actually measure

    Tests such as anti-Müllerian hormone (AMH), antral follicle count (AFC) on ultrasound and follicle-stimulating hormone (FSH) are used to estimate ovarian reserve. They are population-level estimates: they describe a range, not a precise inventory. AMH and FSH can vary between cycles and between laboratories, and AFC depends partly on who performs and reads the scan. A single result is a snapshot, and repeating a test does not necessarily give a truer picture.

    What these tests are reasonably good at is helping a clinician anticipate how you might respond to ovarian stimulation and discuss starting doses or protocol options. What they cannot do is predict the quality of the eggs you do produce, whether a given egg will fertilise, or whether a resulting embryo will have a normal chromosome number. Those are separate questions, and each has its own uncertainty.

    Quantity and quality are different questions

    A low reserve mainly raises the possibility of a smaller number of eggs collected in a cycle. It does not mean those eggs are poor. Egg quality is influenced strongly by age, and it varies from egg to egg even within the same cycle. This is why two people with similar AMH values can have very different experiences, and why a clinician will usually weigh your age and prior response alongside the test result rather than reading the number in isolation.

    It also helps to separate the stages between an egg and a transfer. A retrieved egg must be mature, fertilise, develop into a blastocyst, and — if testing is planned — survive biopsy and produce a usable result. Each stage can reduce the number available at the next. A low starting count therefore does not translate neatly into a low final count, and a higher count does not guarantee a larger number of embryos suitable for transfer.

    Where PGT fits, and where it does not

    Preimplantation genetic testing is sometimes raised in low-reserve conversations, but it is not automatically part of every plan. PGT-A assesses chromosome number in cells sampled from an embryo; it has limitations and can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. PGT-M concerns a known single-gene condition, and PGT-SR concerns chromosomal structural rearrangements — different questions from PGT-A. Whether any of these tests is appropriate depends on your history and should be discussed with your treating team and a genetic counsellor where relevant.

    With a small number of embryos, the practical value of testing becomes a genuine trade-off rather than a default. Biopsy itself carries a risk of damage that can prevent further development, and a mosaic result is inferred from intermediate findings in a sample — it does not establish the cell composition of the whole embryo. These are reasons to ask how a result would change your decisions before committing to testing, not reasons to rule it out. For background on reading a PGT-A quotation, see PGT-A testing cost in Thailand.

    What else changes how a number should be weighed

    • Age: the same AMH means something different at 32 and at 42, because age shifts the expected proportion of eggs with normal chromosomes.
    • Prior stimulation response: how you responded before is often more informative for planning than a test alone.
    • Sperm findings: semen analysis results affect fertilisation and embryo development independently of your reserve. Reading count, movement and morphology together is more useful than any single value — see reading a semen analysis as one picture.
    • Uterine and other findings: the lining and cavity matter to implantation regardless of how many eggs were collected.
    • Your goals: an own-egg attempt, openness to donor eggs, timeline, cost tolerance and willingness to repeat cycles all change what a given number implies for you.

    That last point is not a soft consideration. Two patients with identical results can reasonably make different choices, because the question is not only “how many eggs” but “how many cycles, at what cost, with which alternatives, and on what timeline.” If a first cycle yields few mature eggs, it is worth reviewing what happened before deciding what to change — see low egg yield or few mature eggs in one cycle.

    A worked planning example

    Suppose a 38-year-old patient has a low AMH and is considering treatment in Thailand. A useful planning conversation would not stop at the number. It would cover: what her prior response suggests about stimulation; whether a modest egg yield makes PGT-A a reasonable trade-off or an unnecessary step; how many cycles she is prepared to consider; whether donor eggs should be discussed now rather than after several attempts; and what her timeline allows for travel. None of those answers comes from the AMH value alone, and none should be settled before a clinician reviews her records. For the travel-specific version of this discussion, see IVF in Thailand with diminished ovarian reserve.

    Questions worth putting to your treating doctor

    • Which reserve tests were used, and how much variation should I expect if they are repeated?
    • Given my age and any prior response, what range of egg numbers would you consider plausible for me?
    • How would a low yield change your recommendation on stimulation protocol?
    • Would PGT-A change anything in my plan, and what would we do differently depending on the result?
    • At what point should we discuss alternatives, including donor eggs, and what would that involve?
    • What records from my home clinic would help you assess this properly?

    Interpretation of your results and any treatment recommendation belongs to your treating clinician. A coordinator can help you gather records, prepare a question list and request an appointment or remote consultation, but cannot diagnose or prescribe. If you are comparing quotations, check what each includes before drawing conclusions — itemised price inclusions in Thai IVF explains what to verify.

    The short version

    Ovarian reserve estimates quantity, with real variability. Egg quality, fertilisation, embryo development and chromosome status are separate questions with their own uncertainty. PGT is one option among several, not a requirement, and its value depends on how a result would change your decisions. Your age, history, sperm findings and individual goals all shape what a given egg number means. Treat the number as the opening of the conversation, not its conclusion.

  • Genetic Counselling vs Genetic Laboratory Analysis in PGT: Who Does What

    Patients researching PGT often meet two very different conversations and assume they are the same service. They are not. Genetic counselling is a discussion about what a genetic test could mean for you, your family and your decisions. Genetic laboratory analysis is the technical work that produces a written result from an embryo sample. One is interpretation and support; the other is measurement and reporting.

    Keeping the two separate helps you ask the right person the right question, and it helps you notice when something important has not yet been explained.

    Two different jobs, in plain terms

    Genetic counselling is a conversation, usually with a trained genetics professional, that happens before and after testing. It covers how a condition or chromosome change might be inherited, what a particular test can and cannot detect, what consent involves, how uncertain or unexpected findings might be handled, and what your options are once a result exists. It is where a laboratory result becomes something you can actually reason about.

    Genetic laboratory analysis is the work behind the result. It includes how the embryo sample is handled, which testing method is used, internal quality checks, how findings are classified, and the written report that is issued. The laboratory does not know your family history in the way a counsellor does, and it does not make decisions for you.

    A simple way to hold the distinction: the laboratory tells you what was observed in the sample. Counselling helps you understand what that observation does and does not tell you about the embryo, your options and your next steps.

    What each side can and cannot answer

    Question Genetic counselling Genetic laboratory analysis
    How might this condition be inherited in our family? Yes, this is core counselling work No, not its role
    What does this test detect, and what does it miss? Yes, including limits and uncertainty Yes, for the specific method used
    What was actually observed in this sample? Explains the report with you Yes, this is the laboratory’s finding
    Does this result guarantee a healthy child or a pregnancy? Explains why it does not No, and no test can
    Which option should we choose? Supports your decision; does not decide for you No, not its role
    Who signed and issued this report? May help you locate it Yes, the reporting laboratory

    Neither column replaces your treating fertility clinician, who puts the result together with your medical history and discusses treatment options with you.

    Why a result label is not a full explanation

    PGT results are often described with short labels, and it is tempting to treat a label as a complete answer. It is not. For PGT-A, which assesses chromosome number in cells sampled from an embryo, the HFEA notes that testing has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. That is exactly the gap counselling is designed to address: what a result means, what it does not mean, and how much weight to give it in your situation.

    Mosaic findings show the same point from another angle. The ASRM committee opinion explains that a mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, that technical factors can contribute to such findings, and that a sampled result does not establish the cell composition of the whole embryo. In other words, the laboratory reports what the sample showed; the conversation about what that implies for a transfer decision belongs with your clinician and genetic counsellor.

    This is why a report and a counselling session are not interchangeable. A report can be accurate about the sample and still leave you with real questions that only a discussion can address.

    Different tests, different counselling conversations

    The counselling conversation changes with the test. PGT-M concerns a known monogenic condition, while PGT-SR concerns chromosomal structural rearrangements; the HFEA describes these as addressing different questions, with the treating team and a genetic counsellor discussing the relevant history, test design and suitability. For PGT-M in particular, the laboratory often needs family information to design the test, which is a good example of counselling and laboratory work feeding each other rather than competing.

    If you are weighing a combined approach, the questions worth raising with a genetic counsellor about combining PGT-M and PGT-A are a useful starting point for that conversation.

    How this fits an international PGT journey in Thailand

    When you are arranging testing abroad, the two roles can sit in different places, at different times, and sometimes in different countries. Three practical points are worth confirming early.

    • Who provides counselling, and when. Ask whether pre-test counselling is available remotely before you travel, who provides post-test counselling, and whether it happens by video, phone or in person. Confirm whether an interpreter is needed and who arranges it.
    • Who signs the laboratory report. Ask which laboratory performs the analysis, what the report will contain, and how and when it will be shared with you. A report you cannot read or discuss is of limited use.
    • What happens after you return home. Ask how follow-up questions about a result will be handled once you have left Thailand, and who your point of contact will be.

    If you want to understand how a laboratory pathway is described and verified before committing, the guide to verifying a Thai fertility hospital’s laboratory pathway for PGT sets out what to look for. For the referral and counselling side of a specific test, the PGT-M referral, counselling and lab pathway questions article covers that ground in more detail.

    Where coordination helps, and where it stops

    Coordinating support can help you prepare for both sides of this. That might mean organising your goals, family history details and questions before a counselling appointment, requesting records and reports in a readable form, arranging a remote consultation, or planning how follow-up questions will be handled after you return home. What coordination does not do is interpret your results, diagnose, prescribe or advise on eligibility; those belong to licensed clinicians and genetics professionals.

    If you are comparing quotations for testing, it is worth checking whether counselling sessions, report delivery and follow-up communication are listed as inclusions or left unconfirmed, since a laboratory fee and a counselling fee are not the same item. The guide to understanding and comparing genetic testing fees for IVF is a reasonable place to see how those components are usually separated.

    A short way to remember the difference

    Laboratory analysis answers: what did the sample show, by what method, and who reported it? Genetic counselling answers: what does that mean for us, what remains uncertain, and what are our options? A good PGT pathway gives you both, in the right order, with a named person responsible for each.

    Frequently asked questions

    Can genetic counselling tell me my chance of a successful pregnancy?

    Counselling can explain what a test result does and does not establish, including its limitations, but individual chances are a clinical question for your treating fertility clinician, who considers your full history. No PGT result guarantees a pregnancy or a healthy child.

    If I only have a laboratory report, what is missing?

    A report describes what was observed in the sample and the method used. What is usually missing is the discussion: how much weight the finding carries for your situation, what uncertainty remains, and which options to consider. That conversation belongs with your clinician and a genetic counsellor.

  • What a Separate Incubation Chamber Means in an Embryo Incubator

    When a clinic describes its embryology laboratory, you may hear that embryos are cultured in an incubator with “separate chambers” or “individual compartments.” The phrase sounds reassuring, but it is worth knowing exactly what it describes.

    A separate incubation chamber is a self-contained compartment inside a single incubator unit. Each chamber has its own sealed space, its own gas environment and its own door or access point. Opening one chamber exposes only the embryos inside that compartment to the outside air. The other chambers stay closed.

    That is the core idea. It is a statement about laboratory organisation, not a promise about any individual embryo or pregnancy.

    Shared chamber versus separate chamber: the practical difference

    In a simple incubator with one shared inner space, every time the door opens, the whole interior is disturbed. Temperature drifts, the carbon dioxide level shifts, and the humidity changes until the incubator recovers. If several patients’ embryos or embryos at different culture stages share that space, a routine check on one group affects all of them.

    With separate chambers, the disturbance is confined. A scientist who needs to inspect or handle embryos in chamber three opens only chamber three. Chambers one, two and four keep their set conditions. The recovery period, whatever it is for that particular device, applies to the opened compartment rather than the whole unit.

    This is why the term appears in descriptions of incubation environment control. The aim is to keep each group of embryos in a stable, undisturbed setting for as much of the embryo culture period as possible.

    Why chamber-level separation matters during embryo culture

    Embryos developing in the laboratory are sensitive to their surroundings, and culture typically runs for several days. During that time, embryologists need to look at embryos, change media, and prepare biopsies for genetic testing where that is planned. Each of those tasks means opening something.

    Separate chambers allow a laboratory to organise this work in a few ways:

    • Physical segregation. Embryos from different patients, or embryos at different developmental stages, can be kept in different compartments of the same unit rather than sharing one open space.
    • Contained recovery. When one compartment is opened, the others are not exposed to the same change in gas, temperature or humidity.
    • Limited exposure to a fault. If one chamber needs servicing or develops a problem, the design intent is that the other compartments are not opened or disturbed as part of that work.

    None of these points tells you how well any particular incubator performs, and none of them predicts an outcome for your embryos. They describe how the equipment is built and how a laboratory can use it.

    How monitoring and alarms usually fit in

    Incubators with separate chambers commonly have sensors and alarms that report conditions for each compartment, so staff can see whether one chamber has drifted out of its set range. Some units log temperature and gas readings over time. The details vary by manufacturer and by how a laboratory configures and checks its equipment.

    If you are comparing laboratories, the useful question is not simply “does it have chambers?” but “how are those chambers monitored, who sees the alarms, and what happens when one goes out of range?” A chamber design is only as good as the routine around it.

    What “separate” does and does not guarantee

    It helps to be precise here, because the word can carry more weight than it should.

    What it describes: a physical design in which each compartment is independently sealed and independently accessed, so that work in one does not require opening the others.

    What it does not establish:

    • That the laboratory’s overall culture conditions are better than another laboratory’s.
    • That embryos cultured in separate chambers have a higher chance of implantation, pregnancy or a healthy child.
    • That every chamber is used in the way the design allows, or that each one is independently gas-controlled in practice.
    • That a clinic with this equipment provides better care overall.

    Equipment is one input among many. Media, handling, air quality, staff training, workload and quality-control routines all sit alongside it. A chamber count alone is not a quality ranking, and no single laboratory feature should be treated as one.

    Questions worth putting in writing

    If the incubator design matters to you, ask the laboratory directly and ask for answers you can keep. A short written list is easier to compare across clinics than a conversation you half-remember.

    1. How many independently sealed chambers does the incubator have, and how many patients’ embryos are typically held in each?
    2. Is gas concentration controlled and monitored per chamber, or for the unit as a whole?
    3. How are embryos identified and tracked from the moment they enter a chamber to the moment they are removed? Ask whether there is a double-witness step at each transfer between containers.
    4. What happens if a chamber fails or needs servicing? Is there a backup incubator, and how would embryos be moved and recorded?
    5. Who reviews the chamber alarms, and how quickly are out-of-range readings acted on?
    6. Are temperature and gas readings logged, and can a summary be included in your treatment records?

    These are laboratory-organisation questions, and a well-run laboratory should be able to answer them plainly. If a clinic cannot, that is information too.

    Where this fits if you are also planning PGT

    If genetic testing of embryos is part of your plan, the incubator question sits alongside the testing question rather than replacing it. Embryos that will be biopsied spend time in culture before and after sampling, so how a laboratory manages its incubation environment is part of the wider picture. It does not tell you whether testing is right for your situation.

    PGT-A looks at chromosome number in cells taken from an embryo, and it has limits: it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. PGT-M and PGT-SR address different questions again, and a treating team and genetic counsellor should discuss your history, test design and suitability. Those conversations belong with licensed clinicians, who can also explain what a specific report does and does not mean for you.

    For background on how laboratories choose and combine equipment, see why embryology labs use more than one kind of incubator. If you are weighing up how laboratory standards are described and checked in Thailand, this guide to embryology lab standards sets out what to look for. And if you are still mapping the overall sequence of a treatment cycle, the step-by-step Thailand PGT IVF process shows where laboratory work and testing fit.

    Keeping your own record of what you were told

    Answers about equipment can change as a laboratory upgrades or reorganises. Note the date you asked, who replied, and what was said. If you later compare two clinics, or revisit the question after a previous cycle, that dated note is more useful than a memory of a reassuring phrase.

    If you are preparing questions before approaching a hospital, it helps to organise your goals, timing and priorities first, and to keep a list of which points are confirmed and which are still open. Coordinating that preparation, requesting records, and arranging a remote consultation are things a patient coordinator can help with; interpreting your results and advising on your treatment are for your treating clinicians.

  • High-Magnification Sperm Observation: What It Can Show and What It Cannot Establish

    High-magnification sperm observation is a laboratory technique for looking at individual sperm at far greater magnification than a routine semen analysis uses. In the context of IVF, it is usually discussed alongside a technique called IMSI (intracytoplasmic morphologic sperm injection), in which sperm are examined at very high magnification before one is chosen for injection into an egg. The HFEA, the UK fertility regulator, describes IMSI as selecting sperm for ICSI using microscopy above 6000x magnification.

    The practical question for patients is narrower than the marketing often suggests: what does this extra detail actually tell you, and where does its usefulness stop? This guide separates those two things.

    What the extra magnification can show

    At high magnification, an embryologist can examine features of an individual sperm head that are hard to assess at the magnification used in standard ICSI. These typically include the overall shape of the head, the smoothness of its outline, and the presence and size of vacuole-like structures within the head. The laboratory can then describe or classify sperm according to those visible features and, in an IMSI cycle, tend to prefer sperm whose heads look more regular when choosing which one to inject.

    In other words, high-magnification observation is a descriptive, selection-oriented tool. It produces a detailed picture of sperm morphology at the level of the single cell. That is a genuine piece of information, and it is more granular than the head-shape assessment in a routine semen analysis report.

    What it cannot establish

    The confusion usually arises when a detailed image is treated as a prediction. A few boundaries are worth stating plainly:

    • It cannot confirm that a chosen sperm will fertilise an egg. Fertilisation depends on many factors on both the sperm and egg side, and appearance under a microscope is not a test of that capacity.
    • It cannot establish that an embryo will be chromosomally normal. Sperm morphology seen at high magnification is not a substitute for embryo testing such as PGT-A, and neither test guarantees the other’s result.
    • It cannot predict implantation or live birth for an individual cycle. Those outcomes depend on the embryo, the uterus, the patient’s health and other clinical factors.
    • It does not diagnose the cause of male infertility and does not replace a standard semen analysis, hormone testing or genetic testing where those are indicated.
    • It does not show that IMSI improves outcomes for everyone. The HFEA reports insufficient moderate- or high-quality evidence to rate whether IMSI improves the chance of having a baby, including for male-factor infertility, and states that the reviewed evidence does not support using IMSI over standard ICSI.

    That last point is the evidence boundary. A technique can be technically capable of showing more detail without that detail having been shown to change the chance of a baby. Those are different claims, and clinics sometimes blur them.

    Why the evidence question is separate from the image quality

    It is easy to assume that sharper images must mean better results. The HFEA’s assessment is a useful corrective: the question is not whether high magnification produces clearer pictures, but whether using those pictures to choose sperm changes outcomes in a way that has been reliably demonstrated. On the current assessment, that has not been established.

    This does not mean the technique is harmful or that no one should discuss it. It means the honest framing is “this is what we can see” rather than “this is what we can promise.” If a clinic presents high-magnification selection as improving your chances, it is reasonable to ask what evidence they are relying on and whether it applies to your situation.

    How to read a clinic’s description of the method

    Descriptions of sperm selection vary, and the same words can mean different things in different laboratories. When you read a clinic’s material or hear it in a consultation, it helps to separate three layers:

    1. What is observed. Is the laboratory describing sperm head shape, vacuoles, or another feature? Is the observation used only for information, or does it change which sperm is injected?
    2. What is selected. In an IMSI cycle, which sperm are actually chosen for injection, and who makes that decision?
    3. What is claimed. Does the clinic describe the technique as a selection tool, or does it imply an outcome benefit? If the latter, what is the basis?

    These are clinical questions, and they are appropriate to put to the treating doctor or embryologist. A coordinator can help you organise the questions and the records, but the interpretation of your results and the recommendation for your cycle belong with the clinical team.

    Practical questions about the cycle and the fee

    If high-magnification selection is offered as part of your IVF plan, the practical details matter as much as the science. Consider confirming:

    • Whether the technique is included in the standard ICSI fee or charged as a separate add-on, and how that fee is structured (per cycle, per attempt, or otherwise).
    • Whether the laboratory performs the observation for all sperm injections in the cycle or only in selected cases.
    • What happens if, on the day, the sample does not contain sperm that meet the laboratory’s criteria for selection.
    • Whether the embryologist who performs the selection will document what was observed, and whether that documentation will be in your records.

    Cost questions are worth asking early, because add-on charges can sit outside a quoted package. A general guide to how add-on costs are typically presented can help you frame the conversation, and a direct comparison of two selection methods can clarify what each one does and does not claim.

    Where this fits in a broader plan

    High-magnification observation is one small decision inside a larger IVF plan. If male-factor infertility is part of your history, the more consequential questions are usually about the overall approach: which fertilisation method is planned, whether embryo testing is being considered and why, and what the laboratory will document. Those topics are covered in more depth in the linked guides on male-factor considerations and on PGT-A, which explain what embryo testing can and cannot tell you.

    For international patients, the practical layer is records and communication. Ask for the laboratory’s description of the method in writing, keep your semen analysis reports together with any add-on documentation, and confirm who will answer follow-up questions after you return home. If you would like help organising those questions or requesting records from a hospital, the coordination service can assist with that administrative work; it does not diagnose, prescribe or interpret results.

    The short version

    High-magnification sperm observation can show detailed features of individual sperm heads and support a more informed selection of sperm for injection. It cannot establish that a selected sperm will fertilise, that an embryo will be chromosomally normal, that implantation will occur, or that the technique improves the chance of a baby for you. The evidence assessment does not currently support IMSI over standard ICSI. Treat the technique as a description tool, ask what is being claimed and how it is charged, and keep the clinical interpretation with your treating team.

  • A Mosaic Embryo Result: What to Discuss With Your Clinical Team

    A mosaic embryo result often arrives as a short line in a laboratory report and a much longer list of questions at home. The result describes what was seen in the cells that were sampled and analysed. It does not, by itself, tell you what to do next. That conversation belongs with the clinicians who know your history, your report and the laboratory that produced it.

    This guide is about preparing for that conversation well: what to bring, what to ask, and how to keep separate ideas that are easy to blur together. It is written for international patients who may be reading a report in a second language, at a distance from the clinic, or before a remote appointment.

    Start with the report, not the percentage

    The most common mistake is to treat a mosaic percentage as a universal threshold with a fixed meaning. Laboratories differ in how they define and report mosaicism, and a mosaic result has to be interpreted in the context of the laboratory that issued it. Professional guidance from ASRM makes this point directly: mosaic reporting categories and thresholds can differ between laboratories, and a mosaic result requires interpretation in the context of the reporting laboratory.

    That has a practical consequence for your appointment. Instead of asking only “is 30% bad?”, ask your team to walk you through how this laboratory defines and reports mosaicism, what its validated thresholds are, and what the report’s own wording says about confidence and limitations. The same number can carry different weight depending on the assay, the validation behind it and the way the result is expressed.

    It also helps to know what the test itself can and cannot do. PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations and can produce incorrect findings. A result does not guarantee a successful pregnancy or a healthy child. Your team should be able to explain where those limits sit for your specific report.

    Separate three different questions

    Mosaic conversations go sideways when three separate questions get merged. Ask your clinicians to address each one on its own:

    • What did the laboratory report? The reported mosaic percentage, the chromosome or chromosomes involved, whether the finding is full or segmental, and how the laboratory describes its own confidence.
    • What does that mean for the whole embryo? The biopsy samples a small number of cells. A result is an inference about the embryo from that sample, not a complete map of every cell. Ask how much uncertainty your team attaches to the finding.
    • What would it mean for a pregnancy? Any personal risk figure is a separate clinical discussion that depends on the chromosome involved, your history and other factors. Ask your team to explain what is and is not known for your situation, rather than borrowing a number from a general article.

    Keeping these apart makes the appointment more useful. You are not asking for one reassuring sentence; you are asking for a structured explanation you can understand and record.

    What to bring and what to request in writing

    Bring the full laboratory report, not a summary message. If you have had earlier cycles or testing, bring those reports too, because context across cycles can matter to the interpretation. Note the embryo identifiers exactly as they appear, so there is no confusion about which embryo is being discussed.

    A short records checklist for the appointment:

    • The complete PGT report, including any footnotes, thresholds or classification notes
    • Embryo identifiers and the day of biopsy or freezing, as recorded by the clinic
    • Prior PGT or IVF cycle reports, if any
    • Relevant genetic or medical history your team has asked about
    • Your written question list, in the order that matters most to you

    During or after the appointment, ask which points can be confirmed in writing, such as the laboratory’s reporting categories, the clinic’s general approach to mosaic embryos, and the next appointment or decision point. A written summary is easier to re-read calmly and to share with a partner or another clinician.

    Questions about transfer policy and follow-up

    If transfer of a mosaic embryo is being considered, the discussion should cover more than the percentage. Useful questions include:

    • How does this clinic describe its approach to mosaic embryos, and where is that policy written down?
    • Does the chromosome involved, or whether the finding is full or segmental, change how the team would discuss this embryo?
    • What alternatives would the team want you to understand before deciding, including waiting, further testing or another cycle?
    • If transfer goes ahead, what prenatal follow-up discussion would be offered, and who would lead it?
    • What would the team want to know from you before making a recommendation?

    These are clinical questions, and they belong with your treating clinicians. A coordination service can help you organise and send them, but it does not interpret results or recommend treatment.

    Preparing for a remote consultation

    Many international patients first discuss a mosaic result by video or phone. A little preparation makes that format work better. Send the full report and your question list ahead of time if the clinic allows, and confirm the appointment time in your own time zone. Ask whether an interpreter is available and whether the consultation can be recorded or summarised in writing.

    If you are comparing how different clinics handle mosaic results, it can help to read broadly first. A general guide to interpreting PGT-A results, including mosaic embryos, and an explanation of what embryo biopsy can and cannot reveal give useful background before you speak. For a closer look at how reports are structured, see how to read a PGT-A laboratory report.

    After the appointment: records and handover

    Before you leave Thailand, or before a remote consultation ends, agree how records will reach you and your home clinicians. Ask for the report, the consultation summary and any written policy you discussed. Confirm who will answer follow-up questions and by what method. If you are returning home, a clear handover plan avoids repeating the same conversation from scratch with a new team.

    If you would like help organising your question list, gathering records or arranging a remote consultation, you can request a case review. Coordination support can prepare and communicate; the clinical interpretation and any treatment recommendation remain with your licensed clinicians.

    Sources: Mosaic reporting categories and thresholds can differ between laboratories, and a mosaic result requires interpretation in the context of the reporting laboratory. — ASRM mosaic PGT-A committee opinion, 2023, Fertil Steril 120:973-982 (checked 2026-10-15).

  • What PGT Can and Cannot Tell You About Recurrent Pregnancy Loss

    Recurrent pregnancy loss is a frustrating diagnosis, and it is understandable to look for a test that promises an explanation. Preimplantation genetic testing (PGT) is often raised in that search. It deserves a clear answer about scope: PGT examines embryos created in an IVF cycle. It does not investigate why previous pregnancies were lost, and it does not treat the conditions that cause most losses.

    That does not make PGT irrelevant. It means the test answers a narrower question than many patients expect, and the value of that answer depends on what else has been assessed.

    What PGT actually examines

    PGT is an umbrella term for several tests performed on a small sample of cells taken from an embryo, usually at the blastocyst stage. Each type addresses a different question:

    • PGT-A looks at chromosome number in the sampled cells. It is used to identify embryos with an abnormal number of chromosomes, a finding called aneuploidy.
    • PGT-SR is designed for people who carry a known chromosomal structural rearrangement, such as a balanced translocation. It looks for the specific imbalance that rearrangement could pass on.
    • PGT-M is designed for a known single-gene (monogenic) condition that runs in a family.

    These are different tests with different purposes, and they are not interchangeable. The comparison of PGT-A, PGT-M and PGT-SR sets out how the questions differ. In a recurrent loss discussion, PGT-A is the type most often raised, because chromosome errors in the embryo are a recognised contributor to early miscarriage. PGT-SR only becomes relevant if a structural rearrangement has actually been found in one partner, and PGT-M only if a specific monogenic condition has been identified.

    Why a normal PGT-A result does not close the investigation

    PGT-A screens the embryo. It does not examine the uterus, the endocrine system, the immune system, blood clotting, parental chromosomes, or the many other factors that clinical assessment of recurrent loss considers. A couple can have embryos that test as having the expected chromosome number and still experience a miscarriage, because the cause in that pregnancy lay outside the embryo’s chromosome count.

    This is the central limit. PGT-A can reduce the chance that an embryo with an abnormal chromosome number is selected for transfer. It cannot lower the risk that comes from non-chromosomal factors, and it cannot tell you why earlier losses happened. A result from an embryo biopsy is not a diagnosis of the couple, and it is not a substitute for the standard workup of recurrent loss, which may include parental karyotyping, imaging of the uterus, and other investigations your clinician considers appropriate.

    Where the evidence itself has limits

    Even within its own scope, PGT-A is not a certainty machine. Several technical and interpretive limits matter when you are weighing it:

    • Sampling. The test reads cells from a biopsy, not the whole embryo. A sampled result does not establish the cell composition of the entire embryo.
    • Mosaic results. Sometimes the laboratory reports an intermediate chromosome finding, described as mosaicism. This is inferred from the biopsy findings, and technical factors can contribute to such results. What a mosaic result means for a particular embryo should be discussed with the treating clinician and a genetic counsellor.
    • Incorrect or inconclusive findings. PGT-A can produce results that do not reflect the embryo accurately, and some samples do not yield a usable answer.
    • Biopsy itself. Removing cells from an embryo carries a risk of damage that can affect further development.
    • No guarantee. A PGT result does not guarantee a successful pregnancy or a healthy child.

    These points come from regulator and professional-society patient information, and they are general. They are not a prediction about your embryos or your chances. The guide to what PGT-A screens and who it may help covers the test’s purpose in more detail.

    Separating the embryo factor from other factors

    A useful consultation does not ask “should we do PGT?” in isolation. It asks your clinician to separate two questions: what role, if any, embryo chromosome problems may have played in your losses, and what other factors have been assessed or still need assessment. Those are different lines of enquiry, and only the second can address causes such as uterine, endocrine, immune or clotting-related conditions.

    You can ask directly:

    • Which investigations have already been done for our losses, and which are still outstanding?
    • Has parental karyotyping been performed, and does it change whether PGT-SR or PGT-M is relevant for us?
    • If we use PGT-A, what would a normal result change in our plan, and what would it not change?
    • How would a mosaic or inconclusive result be handled in our case?
    • What alternatives exist if we decide against embryo testing?

    These are clinical questions, and they belong with a licensed clinician who can see your history. A coordination service can help you organise the conversation and the records, but it does not interpret results or advise on treatment.

    Records worth bringing to a PGT conversation

    Recurrent loss discussions go better when the history is documented rather than recalled. A practical record set includes:

    • A dated list of previous pregnancies and losses, with gestational age where known.
    • Any prior loss workup: blood tests, imaging, uterine assessment, and pathology reports if tissue was examined.
    • Parental karyotype results, if performed.
    • Any genetic counselling letters or reports of a known familial condition.
    • Current medication list and relevant past medical history.

    Approximate dates are fine if exact ones are not available; write down what you know and mark what is uncertain. Do not stop or change any medication in preparation for a consultation unless your prescribing clinician tells you to.

    Planning the conversation, including from abroad

    If you are considering treatment in Thailand, the practical work starts before any appointment. A short written summary of your history, a question list, and a clear note of which records are still missing will make a remote consultation more useful. It also helps to ask, in writing, what the hospital needs from you, in what format, and whether a remote discussion is possible before travel.

    For patients comparing options, it can help to read broadly about how PGT is discussed for recurrent loss in Thailand, for example this cautious guide to PGT and recurrent miscarriage, and to keep provider shortlists as a separate research task rather than a substitute for clinical assessment. If you want a starting point for that separate comparison, the countrywide shortlist of IVF hospitals and clinics is an editorial overview, not evidence that any provider produces better outcomes.

    Thailand PGT can help organise records, prepare a question list, request appointments or remote consultations, and coordinate follow-up communication after you return home. Scope and any fees are confirmed individually, and clinical decisions remain with your treating clinicians.

    Frequently asked questions

    Does PGT-A prevent miscarriage?

    No. PGT-A screens embryos for chromosome number, so it can reduce the transfer of embryos with an abnormal count. It does not prevent miscarriage caused by factors outside the embryo's chromosomes, and it cannot guarantee a pregnancy or a healthy child.

    Should everyone with recurrent pregnancy loss have PGT?

    There is no single answer that applies to everyone. Whether PGT is appropriate depends on your history, what investigations have already been done, and what you and your clinician are trying to learn. It is not a replacement for the standard assessment of recurrent loss.

  • When PGT Leaves No Embryo for Transfer: What to Ask Your Clinician

    A cycle can end with no embryo available for transfer even when stimulation, retrieval and fertilisation appeared to go to plan. When PGT is part of the cycle, the news often arrives as a short message or a report with numbers and classifications that are hard to interpret on your own. The most useful next step is usually a scheduled conversation with the clinician who knows your cycle, armed with specific questions about the report and about what the result does and does not tell you.

    This guide is about preparing that conversation. It does not interpret your result or recommend a treatment. Those decisions belong to your treating clinician and, where relevant, a genetic counsellor.

    Start with the report itself

    Before the appointment, ask for the full written laboratory report, not only a summary message. Read it alongside these questions:

    • How many embryos were biopsied? The number tested is the denominator for everything else. A result based on one or two embryos carries different weight from one based on several.
    • What happened to each embryo? Ask for a line-by-line explanation: which embryos were reported as having an abnormal chromosome number, which were reported as mosaic, which gave no result or an inconclusive result, and which were not tested at all.
    • Was any embryo left untested or still in culture? Sometimes an embryo did not reach the biopsy stage, or a decision was made not to test one. Confirm whether anything remains frozen or under observation.
    • What do the laboratory’s own categories mean? Thresholds and reporting categories are laboratory-specific. Ask the clinician to explain the terms used in your report rather than relying on general definitions you have read online.

    PGT-A assesses chromosome number in cells sampled from an embryo, and testing has limitations: it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A). That matters here: a report of no transferable embryo is a statement about the sampled cells and the laboratory’s classification, not a complete account of every embryo’s potential.

    If your report uses the word mosaic, ask what it meant in your case. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo (ASRM: mosaic PGT-A results). The clinician and genetic counsellor should explain what this means for your situation and what uncertainty remains.

    If your testing was PGT-M or PGT-SR rather than PGT-A, the questions shift. PGT-M concerns a known monogenic condition, PGT-SR concerns chromosomal structural rearrangements, and the two address different questions; the treating team and a genetic counsellor should discuss the relevant history, test design and suitability (HFEA: PGT-M and PGT-SR). Ask whether the outcome reflects the condition the test was designed to detect, a technical limitation of the test, or something else.

    Ask why, in stages

    “Why did this happen?” is really several questions. Work through them in order, because the answer at each stage shapes what is worth discussing next.

    1. Stimulation and retrieval. How many eggs were retrieved, how many were mature, and how does that compare with what your clinician expected for your profile?
    2. Fertilisation. How many eggs fertilised, and which fertilisation method was used? Ask whether the method is being reconsidered and on what basis.
    3. Development to biopsy stage. How many embryos reached the stage needed for testing? Embryo development can arrest before testing, which is a different problem from a tested embryo being classified as unsuitable.
    4. The test result itself. Of those tested, how many were classified in each category, and does the pattern suggest a biological factor, a laboratory or technical factor, or chance?
    5. What remains uncertain. Ask directly: is there anything in this cycle that you would investigate further before another attempt?

    Factors such as maternal age, sperm factors and previous cycle history may be relevant, but only your clinician can weigh them for you. Ask which factors they consider most important in your case and why.

    Discuss individual options, not a menu

    There is no standard next step after a cycle with no transferable embryo. The options your clinician raises may include repeating a cycle with changes to stimulation or laboratory approach, further investigations, considering donor gametes or embryos where lawful and available, pausing treatment, or stopping. Each carries different medical, practical and emotional implications.

    Useful questions include:

    • What would you change in another cycle, and what evidence supports that change?
    • What would you expect to be different, and what would remain uncertain?
    • Are there investigations you would recommend before another cycle?
    • What are the alternatives if another cycle is not something we want to pursue now?
    • What is the realistic timeline for deciding, and does waiting affect anything?

    Ask for the reasoning behind any recommendation, including its limits. A clinician should be able to explain why an option is being suggested for you specifically, not only in general.

    Plan the conversation and the follow-up

    If you are arranging care from abroad, a remote consultation may be the practical way to have this discussion. Before booking, confirm the format, who will attend, whether a genetic counsellor will be included, and what records the clinician wants in advance. Sending the full laboratory report, cycle summary and any previous treatment records ahead of time makes the conversation more productive.

    During the appointment, take notes or ask permission to record. Ask for the clinician’s written summary afterwards, and confirm what has been added to your file. If you want a second opinion, request copies of the laboratory report, embryology records and cycle medication history in a format you can share.

    Practical support can sit alongside the clinical conversation without replacing it. A coordination service can help organise your questions and records before the appointment, request documents from the hospital, and arrange remote consultation times. It does not interpret results or advise on treatment. If you are weighing where to continue care, background reading on how to read a PGT-A report from a Thai laboratory and on what PGT testing can and cannot change about success rates may help you frame questions, and a guide to the fertility doctor’s role during a PGT IVF cycle can clarify who is responsible for what.

    If you are considering another cycle in Thailand, it is also reasonable to ask how a future frozen transfer would be planned; the parts of a frozen embryo transfer plan to confirm with your doctor lists the practical points. And if you return home before deciding, follow-up after returning home explains how to keep records and questions moving between countries.

    Look after the practical and emotional side

    Give yourself time before making a decision. Ask whether the clinic offers counselling or a follow-up appointment specifically to discuss the cycle, and whether a genetic counsellor is available. Write down what you understood and check it at the start of the next conversation. If you feel pressure to decide quickly, say so and ask what genuinely needs to be decided now versus later.

    One cycle’s result is information, not a verdict. The purpose of the conversation is to understand what the report shows, what remains unknown, and which choices are yours to make with clinical guidance.

    Frequently asked questions

    Does a report of no embryo for transfer mean another cycle will have the same result?

    Not necessarily. The outcome of one cycle reflects that cycle's eggs, sperm, embryo development and testing results. Your clinician can explain which factors are likely to recur and which might change with a different approach, but no one can predict a future cycle's result.

    Can I ask for the laboratory report even if the clinic has already explained the result?

    Yes. Asking for the full written laboratory report is reasonable and helps you prepare specific questions. A coordination service can help request the document from the hospital; interpretation remains with your treating clinician and genetic counsellor.

  • Repeated Blastocyst Culture Failure or Few Usable Embryos After PGT: What to Review Before Treatment in Thailand

    When several cycles have ended before blastocyst stage, or PGT has left only one or two embryos that could be considered for transfer, the next attempt is rarely helped by simply booking another cycle. What tends to change the conversation is a clear, dated record of what the laboratory actually observed and what the genetic report actually said. That record is what a treating clinician in Thailand — or anywhere — needs in order to review your history rather than start from scratch.

    This guide is about preparation, not prediction. It explains which documents to collect, how to summarise culture and PGT outcomes in a way a clinic can use, and which questions belong with a licensed clinician rather than with a coordinator. Decisions about testing, embryo selection and whether another cycle is appropriate are clinical and individual; no article can tell you your chances.

    Start with the two separate questions hiding in your history

    “Repeated failure” can describe two different problems, and they are reviewed differently:

    • Development before testing. Embryos that slow down, arrest, or never form a blastocyst. The relevant evidence sits in the embryology laboratory’s day-by-day records.
    • Results after testing. Blastocysts formed and were biopsied, but few or none were reported as suitable for transfer after PGT. The relevant evidence sits in the genetic testing report.

    Many patients have some of both. Keeping them separate in your own summary helps a clinician see where the bottleneck may lie — and prevents a PGT report from being read as an explanation for problems that happened before any biopsy.

    Build a dated record set before you contact any clinic

    Clinics can only review what they can read. Ask each previous clinic for copies of the following, and note the date and source of every document. If a report is missing, record that it is missing rather than reconstructing it from memory.

    • Cycle summaries for each attempt: start date, protocol name, and the outcome recorded by the clinic.
    • Stimulation and medication details: which medications, doses, monitoring results and trigger timing, as recorded in your file.
    • Embryology or laboratory reports: fertilisation method, day-by-day embryo development, blastocyst formation, biopsy and vitrification details (see the next section).
    • PGT reports with embryo-level classifications, not just a total count.
    • Prior uterine and medical workup: any imaging, procedures, blood tests or other investigations already completed, with dates.
    • Transfer history, if any embryos were transferred, including how each transfer was managed.

    If you are earlier in the process and simply have few embryos, the preparation steps in Few Usable Embryos: What to Prepare and Ask Before IVF in Thailand overlap closely with this list.

    How to summarise culture outcomes so a laboratory can follow them

    An embryology report is most useful when it is specific. Where your records allow, summarise each cycle in a short table or list covering:

    • Fertilisation method used (for example, conventional insemination or ICSI) and the number of eggs retrieved, mature, and fertilised.
    • Cleavage and blastocyst development: how many embryos were still developing on each recorded day.
    • Arrest timing: the day on which embryos stopped developing, if the laboratory recorded it.
    • Blastocyst formation rate for that cycle, as stated in the report.
    • Biopsy and vitrification details: how many blastocysts were biopsied, how many were frozen, and on which day.

    If the laboratory used a grading system, include the grades exactly as written rather than translating them. Different clinics use different schemes, and a clinician will interpret them in context. What matters is that the original wording survives the transfer between clinics.

    How to summarise PGT results without flattening them

    A single line such as “two normal embryos” loses most of the information a clinician needs. The test type matters, because PGT-A, PGT-M and PGT-SR answer different questions: PGT-A assesses chromosome number, PGT-M concerns a known single-gene condition, and PGT-SR concerns chromosomal structural rearrangements, as the HFEA’s patient information on PGT-M and PGT-SR explains. If you are unsure which test you had, that is itself a question for the reporting laboratory.

    For each testing round, record:

    • the test type performed and the reporting laboratory;
    • the number of embryos biopsied;
    • the counts reported as euploid, aneuploid, mosaic or inconclusive, per embryo where the report gives that detail;
    • any comments or limitations the laboratory included.

    Two points are worth holding in mind. First, PGT-A is a test with limitations and can produce incorrect findings; a result does not guarantee a successful pregnancy or a healthy child, as the HFEA’s PGT-A information notes. Second, a mosaic result is inferred from intermediate findings in a small biopsy sample, and technical factors can contribute to such findings; the sample does not establish the cell composition of the whole embryo, according to the ASRM committee opinion on mosaic PGT-A results. That is why the original report, with its wording, is more useful than a summary.

    If the accuracy and limits of chromosome screening are part of what you want to understand, Understanding PGT-A Accuracy in Thailand covers that ground in more depth.

    What to put in front of a treating clinician

    Once the records are assembled, the review conversation can focus on your actual history. These are clinical questions, and they belong with a licensed clinician who can see your reports — not with a coordination service, which does not diagnose or prescribe.

    • What do my culture records suggest about where development is being lost, and does that change how a next cycle would be planned?
    • Were there laboratory factors in my previous cycles that are worth understanding — for example, how embryos were cultured, selected for biopsy, or frozen?
    • Given my PGT report, how should the reported categories be interpreted for my case, including any mosaic or inconclusive results?
    • Is further testing — of embryos, of me, or of a partner — likely to change a decision, or would it add information without changing the plan?
    • Would a different approach be reasonable to discuss, and what would it be intended to address?
    • What are the uncertainties, and what would you want to review again before deciding?

    It is reasonable to ask about individual chances and risks directly. A clinician can discuss them for your situation; what no one can offer is a guarantee of embryos, pregnancy or a healthy child.

    Turning the review into a practical plan

    Records work is the slowest part of preparing for treatment abroad, so start it early. A coordination service can help organise the documents, prepare a dated checklist with outstanding items clearly marked, and communicate document requests and questions to a hospital. Clinicians interpret the results; sharing records requires your agreement on who receives them and how.

    If you want a remote review before travelling, appointment and remote-consultation coordination can request a format, a records list and confirmation of availability and any fees — all subject to the hospital’s confirmation. Travel and language arrangements are best planned around confirmed appointments rather than assumed schedules. And before you return home, decide which records you will ask for and who should receive them, so follow-up questions can be answered without starting over.

    If you are comparing how clinics present their laboratory and testing arrangements, it helps to read shortlists as research starting points rather than as evidence of better outcomes. A countrywide overview of IVF hospitals and clinics in Thailand can orient that comparison; the clinical review of your own records remains the deciding step.

  • Poor Fertilization or Embryo Quality: What to Check Before IVF in Thailand

    A low fertilization rate or a cycle that ended with few usable embryos is frustrating partly because the explanation is often buried in details that never reach the patient. Before you book flights or choose a clinic in Thailand, the most valuable step is usually not another test but a careful reconstruction of what actually happened in the previous cycle — and a conversation with a treating clinician about what those records can and cannot tell them.

    This guide covers what to request from your previous clinic, how to read those documents well enough to ask sensible questions, and how to sequence the review so that travel decisions come after clinical ones rather than before.

    Start with the laboratory report, not the summary

    Patients often arrive at a consultation with a single sentence: “poor fertilization” or “bad embryo quality.” That phrase hides the numbers a clinician needs. Ask the previous clinic for the full embryology record, including:

    • Fertilization method used — conventional IVF, ICSI, or a split approach — and whether it was planned in advance or changed on the day.
    • Egg numbers — how many eggs were retrieved, and how many were mature. Fertilization rate is usually calculated against mature eggs, so a report without this denominator is hard to interpret.
    • Fertilization results — how many eggs fertilized normally, and whether any showed abnormal fertilization patterns.
    • Embryo development — day-by-day numbers, day-3 and day-5/6 grades, and any notes on fragmentation, cleavage timing or arrest.
    • What happened to each embryo — transferred, frozen, biopsied or discarded, and why.

    If the clinic only issues a discharge summary, ask specifically for the embryology laboratory report. It is a different document and it is the one that carries the detail.

    Request the semen analysis in full

    Male-factor findings are a common thread in poor fertilization histories, and the details matter. Ask for the original semen analysis report rather than a verbal summary, including concentration, motility, morphology, volume and any comments the embryologist added on the day of the cycle. If sperm DNA fragmentation testing or a more detailed morphology assessment was done, request those reports too.

    Two cautions are worth knowing before you build a plan around these results. First, sperm DNA fragmentation test methods and their interpretation are not standardised, so a single number should be discussed with a clinician rather than treated as a verdict. Second, add-on sperm-selection techniques marketed after such testing — including magnetic sorting (MACS) and high-magnification selection (IMSI) — have been assessed by the UK fertility regulator as lacking sufficient moderate- or high-quality evidence that they improve the chance of having a baby, including in male-factor infertility. That does not make them forbidden topics; it means a clinic should be able to explain its own reasoning rather than present them as an obvious upgrade. You can read more about planning around sperm findings in IVF for male factor infertility in Thailand.

    Separate the three possible bottlenecks

    “Poor embryo quality” is a description, not a diagnosis. When you review the records, try to place the problem in one of three broad areas, because each leads to different questions:

    Where the cycle faltered What the records should show What to raise with the clinician
    Egg numbers or maturity Retrieved versus mature eggs; stimulation record Whether the previous protocol suited you, and what a clinician would consider changing
    Fertilization Method used; normal versus abnormal fertilization counts Whether the fertilization approach was appropriate and why
    Embryo development Daily cleavage, grading, fragmentation notes, arrest pattern How the lab assesses embryos and what the pattern suggests

    Many cycles show problems in more than one area, and sometimes no clear cause is found. A clinician may also conclude that the previous cycle was simply a low-yield cycle without an identifiable fault. That is a legitimate outcome of a review, and it is better to hear it before travelling than to assume a change of country will change the result.

    Ask how the Thai laboratory fertilizes and grades

    Fertilization method and embryo assessment are clinical decisions made by the treating team, not by a coordination service. What you can reasonably ask before committing is how those decisions are made at the clinic you are considering:

    • Under what circumstances does the team choose conventional IVF, and when does it recommend ICSI? What would prompt that choice in your case?
    • Who performs embryo grading, against what criteria, and will you receive the laboratory report rather than only a summary?
    • Can the laboratory review your previous records in advance, and does that review happen before or during your visit?
    • If embryo quality is again poor, what would the team want to discuss with you at that point?

    If preimplantation genetic testing is part of your history or your questions, keep the distinction clear: PGT-A assesses chromosome number in cells sampled from an embryo, and it has limitations — it can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child. A biopsy also carries a risk of damage that can prevent further development. PGT-M and PGT-SR address different questions again, relating to a known monogenic condition or a chromosomal structural rearrangement. None of these tests repairs embryo quality; they describe or select among embryos that already exist. For background on how laboratories are assessed, see PGT IVF lab quality in Thailand.

    Sequence the work before the travel

    The timing question is really a sequencing question. A practical order looks like this:

    1. Collect records from the previous clinic — embryology report, stimulation record, semen analysis, operative and transfer notes.
    2. Organise them into a dated file with a short cover note listing what is included and what is still outstanding.
    3. Request a remote consultation with the clinic you are considering, sending the records ahead so the clinician can review them before the appointment.
    4. Hold travel bookings until the clinic has confirmed the appointment format, what it can review remotely, and what would need to happen in person.
    5. Plan the return-home handover — which records you will ask for, who should receive them, and which follow-up questions remain open.

    This is where a coordination service can help without crossing into clinical territory: assembling the record set, sending document requests to the hospital, arranging the remote appointment, and later requesting records for your own doctor at home. Clinicians interpret the results and make the treatment decisions; coordination does not diagnose, prescribe or promise a particular outcome. If you want to understand what a case review involves, you can request a Thailand IVF case review.

    A worked example of the record set

    Suppose a couple had one cycle abroad that yielded nine eggs, five mature, two fertilized by conventional IVF, and one day-5 blastocyst of moderate grade that did not implant. A useful file for a Thai consultation would contain: the stimulation chart with drug names and doses; the retrieval note confirming nine eggs and five mature; the embryology report showing the fertilization method and the two fertilized eggs; the day-by-day development notes explaining why three embryos arrested; the embryology grading sheet for the blastocyst; a full semen analysis from around that time; and the transfer note. With that file, a clinician can discuss whether the fertilization method was the limiting step, whether maturity was the issue, or whether the picture is unexplained. Without it, the conversation stays at the level of “poor fertilization” and nobody learns much.

    What a review cannot promise

    Prior records inform a consultation; they do not guarantee a different outcome. Fertilization and embryo development vary between cycles, and a change of clinic or country is not itself a treatment. Some patients learn that the previous cycle was unremarkable in hindsight; others learn that a specific, addressable factor was missed. Both are useful, and both are better known before you commit to travel dates. If a cycle has already failed and you are deciding what comes next, preparing for a failed IVF cycle covers the emotional and practical side of that decision.

    One practical reminder: keep your own dated copy of every record you send, and do not change any medication while you wait for a consultation — that instruction belongs to your treating clinician.

    Frequently asked questions

    Can a Thai clinic tell from my old records why fertilization was low?

    Sometimes. A full embryology report showing egg maturity, fertilization method and daily embryo development gives a clinician real material to work with. In other cases the records are incomplete or the cycle shows no clear cause, and the review itself becomes the honest answer. Either way, the review is a clinical judgement made by the treating team, not something a coordination service can determine in advance.

    Should I repeat tests before travelling or wait until the consultation?

    That depends on what your records already show and what the clinic asks for. Sending the existing reports first usually avoids duplicating tests that were recently done, but a clinician may still want updated results. Ask the clinic which tests, if any, they want completed before a remote appointment so that you are not arranging them twice.